Modern Vaccine Adjuvant/Formulation—Session 9: Adjuvants

Abstract

The Session 9 of the Modern Vaccine Adjuvant/Formulation meeting pointed out the permanent need for vaccine improvement and for adjuvant development. Indeed, the increasing use of recombinant subunit vaccines for both parenteral and mucosal vaccination necessitates the development of improved adjuvants. This session dealt with strategies for the development of new vaccine adjuvants with respect to the availability of new molecules targeting specifically the receptors of the systemic or mucosal immune system.

Keywords: :

• formulation
• adjuvants
• mucosal immunity
• T-cell response

10.4161/hv.26074

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.